SUSAN WOLLENBURG: Open Payments
NPI 1164740478 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$284 in 14 payments from 11 companies in 2025. Trend: 2023 $387 · 2024 $155 · 2025 $284
Food & beverage: $284
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 2 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Medtronic, Inc. | 1 | $25 |
| BioMarin Pharmaceutical Inc. | 1 | $22 |
| SANOFI-AVENTIS U.S. LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Novo Nordisk Inc | 1 | $15 |
| Amgen Inc. | 1 | $14 |
Products named: REXULTI, GEMTESA, QULIPTA, UBRELVY, SYMPLICITY G3, VOXZOGO 1.2mg, TZIELD, MOUNJARO.
Industry payments across NE — which companies pay providers there.
